A BILL 
To clarify the treatment of pass-through status under the 
Medicare outpatient payment system for certain drugs. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Pass-Through Tech-
4
nical Corrections Act’’. 
5
SEC. 2. CLARIFICATION OF PASS-THROUGH STATUS UNDER 
6
MEDICARE OPPS FOR CERTAIN DRUGS. 
7
Notwithstanding section 1301 of the Consolidated 
8
Appropriations Act of 2018 (Public Law 115–141), in the 
9
04:36 Nov 21, 2019
H5057
2 
•HR 5057 IH
case of a radiopharmaceutical drug for which pass-through 
1
status was provided pursuant to section 1833(t)(6) of the 
2
Social Security Act (42 U.S.C. 1395l(t)(6)) and whose pe-
3
riod of pass-through status initially expired on either De-
4
cember 31, 2017, or December 31, 2018, if such radio-
5
pharmaceutical drug is indicated for positron emission to-
6
mography beta amyloid imaging covered under a coverage 
7
evidence 
development 
determination 
under 
section 
8
1862(a)(1)(E) of the Social Security Act (42 U.S.C. 
9
1395y(a)(1)(E)), then such pass-through status shall be 
10
extended until such date that the coverage with evidence 
11
development review is determined by the Centers for Medi-
12
care & Medicaid Services to be completed. 
13
Æ 
04:36 Nov 21, 2019
H5057
